A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain

Study acronym: CPMP
StatusRecruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial arms changed: 12 → 15
    • Interventions modified
    • Study sites revised (64)
  2. Interventions: LY3016859 ISA (Drug), LY3526318 ISA (Drug), LY3556050 ISA (Drug), LY3857210 ISA (Drug), Placebo (Drug), Placebo Oral (Drug) to LY3016859 ISA (Drug), LY3526318 ISA (Drug), LY3556050 ISA (Drug), LY3857210 ISA (Drug), LY4065967 ISA (Drug), Placebo (Drug), Placebo Oral… Show 4 more changesShow less
    • Eligibility criteria shortened, about 11 words
    • Site details revised at 17 of 64 sites
    • Publications: details revised at 1 of 1 entry
    • Study arms: 12 to 15
  3. Site contacts updated at 1 of 64 sitesv22
  4. Study sites: 63 to 64v21
  5. Study sites: 64 to 63v20
Show 18 earlier versionsHide 18 earlier versions
  1. Site details revised at 11 of 64 sitesv19
  2. Site details revised at 1 of 64 sitesv18
  3. Study sites revised (64)v17
  4. Re-verified, no change to tracked fieldsv16
  5. Study sites: 62 to 64v15
  6. Re-verified, no change to tracked fieldsv14
  7. Study sites: 54 to 62v13
  8. Study sites: 56 to 54v12
  9. Site details revised at 2 of 56 sitesv11
  10. Re-verified, no change to tracked fieldsv10
  11. Study sites: 49 to 56
    • Primary and study completion dates: Apr 25, 2027 to Apr 2027
    v9
  12. Site contacts updated at 3 of 49 sitesv8
  13. Study sites: 45 to 49v7
  14. Study sites: 48 to 45v6
  15. Study sites: 49 to 48v5
  16. Study sites: 39 to 49v4
  17. 2 versions Re-verified since Aug 14, 2023, no change to tracked fieldsv2-v3
  1. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Eli Lilly
366 trials monitored
See 16 trials at risk
The purpose of the chronic pain master protocol is to compare independent pain interventions and establish an overarching structure for the disease-state addenda (DSA) and intervention-specific appendices (ISAs). The ISAs may start independently of other ISAs as interventions become available for clinical testing.
Trial Details
NCT Number NCT05986292
Lead Sponsor Eli Lilly and Company
Conditions
(from sponsor)		 Osteoarthritis, Knee, Diabetic Neuropathic Pain, Chronic Low-back Pain
Related terms Osteoarthritis, Knee
Enrollment 10,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov